

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-4. (canceled)
5. (previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) a mature form of the amino acid sequence SEQ ID NO:14;
 - (b) a variant of a mature form of the amino acid sequence SEQ ID NO:14, wherein one amino acid residue in said variant differs from the amino acid sequence of said mature form;
 - (c) SEQ ID NO:14;
 - (d) a variant of the amino acid sequence of SEQ ID NO:14, wherein one amino acid residue in said variant differs from the amino acid sequence of SEQ ID NO:14; and
 - (e) a fragment of SEQ ID NO:14 selected from the group consisting of residues:1-400, 450-520, 750-850, 1100-1200, 1250-1400, 1490-1750, 1760-2300, 2400-2600, and 2650-2725.
- 6-8. (canceled)
9. (currently amended) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
 - (a) SEQ ID NO:13[[],];
 - (b) a nucleotide sequence differing by one nucleotide from a nucleotide sequence of SEQ ID NO: 13[[],];
 - (c) the complement of (a) or (b).
- 10-11. (canceled)
12. (original) A vector comprising the nucleic acid molecule of claim 5.
13. (original) The vector of claim 12, further comprising a promoter operably-linked to said nucleic acid molecule.
14. (original) A cell comprising the vector of claim 12.
- 15-38. (canceled)

39. (currently amended) A composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically-acceptable carrier.
- 40-41. (canceled)
42. (currently amended) A kit comprising in one or more containers, the ~~pharmaceutical~~ composition of claim 39.
- 43-49. (canceled)
50. (previously presented) An isolated nucleic acid molecule comprising the complement of the nucleic acid molecule of claim 5.
51. (previously presented) The nucleic acid molecule of claim 5 wherein the amino acid residue at position 28 of SEQ ID NO:14 is Asp or Gly.
52. (previously presented) The nucleic acid molecule of claim 5 wherein the amino acid residue at position 64 of SEQ ID NO:14 is Val or Ala.
53. (previously presented) The nucleic acid molecule of claim 5 wherein the amino acid residue at position 76 of SEQ ID NO:14 is Ala or Thr.
54. (previously presented) A vector comprising the nucleic acid molecule of claim 9.
55. (previously presented) The vector of claim 53, further comprising a promoter operably-linked to said nucleic acid molecule.
56. (previously presented) A cell comprising the vector of claim 54.
57. (previously presented) The nucleic acid molecule of claim 9 wherein the nucleotide residue at position 117 of SEQ ID NO:13 is A or G.
58. (previously presented) The nucleic acid molecule of claim 9 wherein the nucleotide residue at position 225 of SEQ ID NO:13 is T or C.
59. (previously presented) The nucleic acid molecule of claim 9 wherein the nucleotide residue at position 260 of SEQ ID NO:13 is G or A.